Literature DB >> 19180263

Oral formulations of budesonide: a novel treatment for inflammatory bowel disease.

R Paul Svoboda1, Dhaval H Patel, Kevin W Olden.   

Abstract

Budesonide is a promising drug for a variety of documented applications and has potential in gastroenterology. Its unique local mechanism of delivery and efficient first-pass metabolism, resulting in fewer systemic adverse effects than with conventional glucocorticoids, makes this a desirable drug for clinical practice. This drug has shown promise in treating a wide spectrum of inflammatory diseases from inflammatory bowel disease and other colitides to autoimmune liver diseases. Future research should focus on ways to increase delivery methods to promote long-term usage for maintenance therapy for the disease entities listed above, as well as for other potential nongastrointestinal conditions. Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19180263     DOI: 10.1358/dot.2008.44.11.1297916

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  2 in total

1.  BUDESONIDE-INDUCED HYPEROSMOLAR HYPERGLYCEMIC STATE FOLLOWING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT.

Authors:  Thejus Jayakrishnan; Meera Babu; Steven Goodnow; Brent Hardman
Journal:  AACE Clin Case Rep       Date:  2020-09-21

2.  Gluten-free diet and steroid treatment are effective therapy for most patients with collagenous sprue.

Authors:  Alberto Rubio-Tapia; Nicholas J Talley; Suryakanth R Gurudu; Tsung-Teh Wu; Joseph A Murray
Journal:  Clin Gastroenterol Hepatol       Date:  2010-01-06       Impact factor: 11.382

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.